Work

Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer

Year: 2019

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2019.09.006

Authors: Chia-Chi Hsu, Bin-Chi Liao, Wei-Yu Liao, Aleksandra Markovets, Daniel Stetson, Kenneth Thress, James Chih-Hsin Yang

Institutions: National Taiwan University, National Taiwan University Hospital, AstraZeneca (United States), Tesaro (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Ministry of Science and Technology, Taiwan, National Taiwan University, Genentech, Chugai Pharmaceutical

Awards: Precision Medicine Research Center( II ), G5047284123

OpenAlex ID: W2976431901

FWCI: 7.9

Cites: 33

Cited by: 86

Related to: 10